1-5 of 5
David C. Blakey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR12: Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors

Free
Alexey S. Revenko, Sarah J. Ross, Lyndsey L. Hanson, Rebecca Ellston, Chris May, Sanjay K. Pandey, Linda K. Buckett, Stephanie K. Klein, Mitchell Revill, Kevin Hudson, Brett P. Monia, David C. Blakey, Paul Lyne, Allan R. MacLeod
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR12.
https://doi.org/10.1158/1535-7163.TARG-15-PR12
Published: 01 December 2015
View articletitled, Abstract PR12: Discovery and preclinical evaluation of cEt-modified KRAS antisense oligonucleotide inhibitors
Journal Articles

Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling

Free
Neil R. Michaud, Youzhen Wang, Kristen A. McEachern, Jerold J. Jordan, Anne Marie Mazzola, Axel Hernandez, Sanjoo Jalla, Jon W. Chesebrough, Mark J. Hynes, Matthew A. Belmonte, Lidong Wang, Jaspal S. Kang, Jelena Jovanović, Naomi Laing, David W. Jenkins, Elaine Hurt, Meina Liang, Christopher Frantz, Robert E. Hollingsworth, Diane M. Simeone, David C. Blakey, Vahe Bedian
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 386–398.
https://doi.org/10.1158/1535-7163.MCT-13-0420
Published: 09 February 2014
View articletitled, Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling
Open the PDF for Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling in another window
Includes: Supplementary data
Journal Articles

MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

Free
David W. Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N. Foltz, Brandon C. Clavette, Kathy Manchulenko, Cath Eberlein, Jane Kendrew, Philip Petteruti, Song Cho, Melissa Damschroder, Li Peng, Dawn Baker, Neil R. Smith, Hazel M. Weir, David C. Blakey, Vahe Bedian, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1650–1660.
https://doi.org/10.1158/1535-7163.MCT-11-1027
Published: 08 August 2012
View articletitled, MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo
Open the PDF for MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo in another window
Includes: Supplementary data
Journal Articles

An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding

Free
Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R. Smith, Hazel M. Weir, Stephen R. Wedge, David C. Blakey, Ian Foltz, Joe Zhou, Jaspal S. Kang, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 770–783.
https://doi.org/10.1158/1535-7163.MCT-10-0876
Published: 08 May 2011
View articletitled, An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding
Open the PDF for An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding in another window
Journal Articles

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Free
Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 145–156.
https://doi.org/10.1158/1535-7163.MCT-09-0554
Published: 12 January 2010
View articletitled, A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Open the PDF for A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models in another window
Includes: Supplementary data